JP2002519305A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002519305A5 JP2002519305A5 JP2000556389A JP2000556389A JP2002519305A5 JP 2002519305 A5 JP2002519305 A5 JP 2002519305A5 JP 2000556389 A JP2000556389 A JP 2000556389A JP 2000556389 A JP2000556389 A JP 2000556389A JP 2002519305 A5 JP2002519305 A5 JP 2002519305A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- geranylgeranyl
- group
- composition according
- substituted alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 nitrogen-containing bisphosphonate Chemical class 0.000 description 48
- 239000008194 pharmaceutical composition Substances 0.000 description 23
- 229940122361 Bisphosphonate Drugs 0.000 description 9
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 6
- 125000003118 aryl group Chemical group 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 5
- 229960004343 alendronic acid Drugs 0.000 description 5
- OINNEUNVOZHBOX-QIRCYJPOSA-K 2-trans,6-trans,10-trans-geranylgeranyl diphosphate(3-) Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP([O-])(=O)OP([O-])([O-])=O OINNEUNVOZHBOX-QIRCYJPOSA-K 0.000 description 4
- OINNEUNVOZHBOX-XBQSVVNOSA-N Geranylgeranyl diphosphate Natural products [P@](=O)(OP(=O)(O)O)(OC/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)O OINNEUNVOZHBOX-XBQSVVNOSA-N 0.000 description 4
- OJISWRZIEWCUBN-QIRCYJPOSA-N (E,E,E)-geranylgeraniol Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CO OJISWRZIEWCUBN-QIRCYJPOSA-N 0.000 description 3
- 229940062527 alendronate Drugs 0.000 description 3
- XWRJRXQNOHXIOX-UHFFFAOYSA-N geranylgeraniol Natural products CC(C)=CCCC(C)=CCOCC=C(C)CCC=C(C)C XWRJRXQNOHXIOX-UHFFFAOYSA-N 0.000 description 3
- OJISWRZIEWCUBN-UHFFFAOYSA-N geranylnerol Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCO OJISWRZIEWCUBN-UHFFFAOYSA-N 0.000 description 3
- PAYGMRRPBHYIMA-UHFFFAOYSA-N sodium;trihydrate Chemical compound O.O.O.[Na] PAYGMRRPBHYIMA-UHFFFAOYSA-N 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 2
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 2
- 125000000739 C2-C30 alkenyl group Chemical group 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 125000002350 geranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229940015872 ibandronate Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 2
- 229940046231 pamidronate Drugs 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 229940089617 risedronate Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- ALEWCKXBHSDCCT-YFVJMOTDSA-N (2E,6E)-farnesyl monophosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\COP(O)(O)=O ALEWCKXBHSDCCT-YFVJMOTDSA-N 0.000 description 1
- XFACLYNWBJYMCK-IUBLYSDUSA-N (E,E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl propionate Chemical compound CCC(=O)OC\C=C(/C)CC\C=C(/C)CCC=C(C)C XFACLYNWBJYMCK-IUBLYSDUSA-N 0.000 description 1
- XYLKLVHYQXHUAZ-UHFFFAOYSA-N 1-(5,5-dimethylhexoxy)-5,5-dimethylhexane Chemical compound CC(C)(C)CCCCOCCCCC(C)(C)C XYLKLVHYQXHUAZ-UHFFFAOYSA-N 0.000 description 1
- SHOKIRAUFQBXSP-UHFFFAOYSA-N 1-ethoxy-3,7,11-trimethyldodeca-2,6,10-triene Chemical compound CCOCC=C(C)CCC=C(C)CCC=C(C)C SHOKIRAUFQBXSP-UHFFFAOYSA-N 0.000 description 1
- GNAKABFIXDKLCV-UHFFFAOYSA-N 2-isopropyl-hexanoic acid Chemical compound CCCCC(C(C)C)C(O)=O GNAKABFIXDKLCV-UHFFFAOYSA-N 0.000 description 1
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 1
- GECQKAUDSRLRJA-UHFFFAOYSA-N 3,3-dimethylbutan-2-yl 2-hydroxypropanoate Chemical compound CC(O)C(=O)OC(C)C(C)(C)C GECQKAUDSRLRJA-UHFFFAOYSA-N 0.000 description 1
- ZGIGZINMAOQWLX-NCZFFCEISA-N 3,7,11-Trimethyl-2,6,10-dodecatrienyl acetate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\COC(C)=O ZGIGZINMAOQWLX-NCZFFCEISA-N 0.000 description 1
- 239000001629 3,7-dimethylocta-2,6-dienyl benzoate Substances 0.000 description 1
- VWYTZNPMXYCBPK-UHFFFAOYSA-N 3-bromobenzene-1,2-diamine Chemical compound NC1=CC=CC(Br)=C1N VWYTZNPMXYCBPK-UHFFFAOYSA-N 0.000 description 1
- QTPWDDBKDYJSRE-UHFFFAOYSA-N 4-(3,3-dimethylbutan-2-yloxy)-4-oxobutanoic acid Chemical compound CC(C)(C)C(C)OC(=O)CCC(O)=O QTPWDDBKDYJSRE-UHFFFAOYSA-N 0.000 description 1
- ZNROQYKJUSGZIT-UHFFFAOYSA-N CCCCC1C(=CC=CC1(C)C)C(=O)O Chemical compound CCCCC1C(=CC=CC1(C)C)C(=O)O ZNROQYKJUSGZIT-UHFFFAOYSA-N 0.000 description 1
- ZGIGZINMAOQWLX-UHFFFAOYSA-N Farnesyl acetate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOC(C)=O ZGIGZINMAOQWLX-UHFFFAOYSA-N 0.000 description 1
- VWFJDQUYCIWHTN-UHFFFAOYSA-N Farnesyl pyrophosphate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-UHFFFAOYSA-N 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GVVPGTZRZFNKDS-YFHOEESVSA-N Geranyl diphosphate Natural products CC(C)=CCC\C(C)=C/COP(O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-YFHOEESVSA-N 0.000 description 1
- YDVXYTIIPGKIJP-UHFFFAOYSA-N O-Benzoyl-geraniol Natural products CC(C)=CCCC(C)=CCOC(=O)C1=CC=CC=C1 YDVXYTIIPGKIJP-UHFFFAOYSA-N 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- BYCHQEILESTMQU-UHFFFAOYSA-N Propionsaeure-nerylester Natural products CCC(=O)OCC=C(C)CCC=C(C)C BYCHQEILESTMQU-UHFFFAOYSA-N 0.000 description 1
- IBDUXGXSPANFLU-YEFHWUCQSA-N [(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trienyl] benzoate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\COC(=O)C1=CC=CC=C1 IBDUXGXSPANFLU-YEFHWUCQSA-N 0.000 description 1
- NHYSRKKHKHCRGR-RFRQLJORSA-N [(2e,6e,10e)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl] acetate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COC(C)=O NHYSRKKHKHCRGR-RFRQLJORSA-N 0.000 description 1
- YUIDGONLMDUWNF-UHFFFAOYSA-N ethyl 3-chloro-4h-thieno[3,2-b]pyrrole-5-carboxylate Chemical compound S1C=C(Cl)C2=C1C=C(C(=O)OCC)N2 YUIDGONLMDUWNF-UHFFFAOYSA-N 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229940007703 farnesyl acetate Drugs 0.000 description 1
- HIGQPQRQIQDZMP-UHFFFAOYSA-N geranil acetate Natural products CC(C)=CCCC(C)=CCOC(C)=O HIGQPQRQIQDZMP-UHFFFAOYSA-N 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- HIGQPQRQIQDZMP-DHZHZOJOSA-N geranyl acetate Chemical compound CC(C)=CCC\C(C)=C\COC(C)=O HIGQPQRQIQDZMP-DHZHZOJOSA-N 0.000 description 1
- YDVXYTIIPGKIJP-QINSGFPZSA-N geranyl benzoate Chemical compound CC(C)=CCC\C(C)=C/COC(=O)C1=CC=CC=C1 YDVXYTIIPGKIJP-QINSGFPZSA-N 0.000 description 1
- GVVPGTZRZFNKDS-JXMROGBWSA-N geranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-JXMROGBWSA-N 0.000 description 1
- FFOWJDCTFSWUMJ-JXMROGBWSA-N geranyl phosphate Chemical compound CC(C)=CCC\C(C)=C\COP(O)(O)=O FFOWJDCTFSWUMJ-JXMROGBWSA-N 0.000 description 1
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- CBIDRCWHNCKSTO-UHFFFAOYSA-N prenyl diphosphate Chemical compound CC(C)=CCO[P@](O)(=O)OP(O)(O)=O CBIDRCWHNCKSTO-UHFFFAOYSA-N 0.000 description 1
- MQCJHQBRIPSIKA-UHFFFAOYSA-N prenyl phosphate Chemical compound CC(C)=CCOP(O)(O)=O MQCJHQBRIPSIKA-UHFFFAOYSA-N 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9040198P | 1998-06-24 | 1998-06-24 | |
| US9291998P | 1998-07-15 | 1998-07-15 | |
| GBGB9817172.1A GB9817172D0 (en) | 1998-08-06 | 1998-08-06 | Compositions and methods for inhibiting bone resorption |
| GB60/092,919 | 1998-10-13 | ||
| GB9817172.1 | 1998-10-13 | ||
| GBGB9822330.8A GB9822330D0 (en) | 1998-10-13 | 1998-10-13 | Compositions and methods for inhibiting bone resorption |
| GB9822330.8 | 1998-10-13 | ||
| GB60/090,401 | 1998-10-13 | ||
| PCT/US1999/013967 WO1999067809A1 (en) | 1998-06-24 | 1999-06-21 | Compositions and methods for inhibiting bone resorption |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002519305A JP2002519305A (ja) | 2002-07-02 |
| JP2002519305A5 true JP2002519305A5 (enExample) | 2006-08-10 |
Family
ID=27451815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000556389A Withdrawn JP2002519305A (ja) | 1998-06-24 | 1999-06-21 | 骨吸収阻害用の組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6432931B1 (enExample) |
| EP (1) | EP1088333A4 (enExample) |
| JP (1) | JP2002519305A (enExample) |
| AU (1) | AU757104B2 (enExample) |
| CA (1) | CA2336201A1 (enExample) |
| WO (1) | WO1999067809A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001022963A1 (en) * | 1999-09-27 | 2001-04-05 | Merck & Co., Inc. | Method of preventing osteoporosis |
| KR20030048129A (ko) * | 2000-11-08 | 2003-06-18 | 산텐 세이야꾸 가부시키가이샤 | 파르네실초산을 유효 성분으로 하는 각결막 질환 치료제 |
| EP1380293A4 (en) * | 2001-03-30 | 2009-03-18 | Nisshin Oillio Group Ltd | MEANS TO IMPROVE BONE MATERIAL CHANGE |
| EP1446009A2 (en) * | 2001-11-08 | 2004-08-18 | Merck & Co., Inc. | Compounds useful in the treatment of anthrax |
| CA2469779C (en) * | 2001-12-21 | 2008-02-12 | The Procter & Gamble Company | Method for the treatment of bone disorders |
| US20040052843A1 (en) * | 2001-12-24 | 2004-03-18 | Lerner E. Itzhak | Controlled release dosage forms |
| NZ552514A (en) * | 2001-12-24 | 2008-08-29 | Teva Pharma | Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it |
| CN1939314A (zh) | 2002-05-10 | 2007-04-04 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗和预防骨质疏松症的二膦酸 |
| SI1596870T2 (sl) * | 2002-12-20 | 2011-07-29 | Hoffmann La Roche | Formulacija z visokim odmerkom ibandronata |
| WO2005000858A2 (en) * | 2003-06-27 | 2005-01-06 | Akira Odani | Bisphosphonate complexes |
| JP4738007B2 (ja) * | 2005-02-04 | 2011-08-03 | 久光製薬株式会社 | 骨粗鬆症治療用外用剤 |
| SI1855674T1 (sl) | 2005-03-02 | 2014-10-30 | Merck Sharp & Dohme Corp. | Sestavek za inhibicijo katepsina k |
| US7704656B2 (en) * | 2005-03-23 | 2010-04-27 | Xerox Corporation | Photoconductive imaging member |
| ATE425171T1 (de) * | 2005-12-27 | 2009-03-15 | Ipca Lab Ltd | Verbesserter herstellungsprozess von 4-amino- hydroxybutyliden-1,1-bisphosphonischer säure und ihrer salze |
| US8974801B2 (en) * | 2006-12-21 | 2015-03-10 | Amphastar Pharmaceuticals Inc. | Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate |
| US20080164004A1 (en) * | 2007-01-08 | 2008-07-10 | Anastasia Kolesnichenko | Method and system of electromagnetic stirring for continuous casting of medium and high carbon steels |
| US8882740B2 (en) * | 2009-12-23 | 2014-11-11 | Stryker Trauma Gmbh | Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone |
| US20130085283A1 (en) * | 2011-10-04 | 2013-04-04 | Coyote Pharmaceuticals, Inc. | Geranylgeranylacetone derivatives |
| IN2014CN02585A (enExample) * | 2011-10-04 | 2015-08-07 | Coyote Pharmaceuticals Inc | |
| JP2015514686A (ja) * | 2012-02-29 | 2015-05-21 | コヨーテ・ファーマシューティカルズ・インコーポレイテッドＣｏｙｏｔｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｇｇａ及びそのｇｇａ誘導体組成物並びにこれらを含む麻痺状態を含めた神経変性疾患を治療する方法 |
| WO2014055440A1 (en) * | 2012-10-01 | 2014-04-10 | Coyote Pharmaceuticals, Inc. | Preparation of gga and derivatives thereof and their co-crystallization with urea or thiourea |
| US9119808B1 (en) | 2012-10-08 | 2015-09-01 | Coyote Pharmaceuticals, Inc. | Treating neurodegenerative diseases with GGA or a derivative thereof |
| BR112015013651B1 (pt) | 2012-12-27 | 2020-03-24 | Kimberly-Clark Worldwide, Inc. | Análogo de farnesol, lenço, artigo absorvente, e, método de formação de um análogo de farnesol |
| MX365561B (es) | 2012-12-27 | 2019-06-05 | Kimberly Clark Co | Método para ajustar la solubilidad de un aceite esencial en agua y aceites esenciales modificados solubles en agua. |
| WO2014151719A1 (en) * | 2013-03-15 | 2014-09-25 | Coyote Pharmaceuticals, Inc. | Sublingual formulations including geranylgeranylacetone and geranylgeranylacetone derivatives |
| WO2014151697A1 (en) * | 2013-03-15 | 2014-09-25 | Coyote Pharmaceuticals, Inc. | Therapeutic uses for geranylgeranyl acetone and derivatives thereof |
| KR102363895B1 (ko) * | 2020-03-02 | 2022-02-17 | 영남대학교 산학협력단 | 염증 질환 또는 면역 질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB938712A (en) * | 1961-05-24 | 1963-10-02 | Angeli Inst Spa | Farnesyl acetic esters |
| JPS5612114B2 (enExample) | 1974-06-07 | 1981-03-18 | ||
| JPS5573642A (en) * | 1978-11-28 | 1980-06-03 | Kuraray Co Ltd | Farnesyl-acetic ester derivative |
| US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
| JPS57106644A (en) * | 1980-12-20 | 1982-07-02 | Kotobuki Seiyaku Kk | Farnesence derivative, mucosa stabilizer comprising it as active ingredient, and its preparation |
| IT1201087B (it) | 1982-04-15 | 1989-01-27 | Gentili Ist Spa | Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche |
| US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| US4739073A (en) | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
| US4518528A (en) | 1983-05-19 | 1985-05-21 | Rasnick David W | α Amino fluoro ketones |
| US4933165A (en) | 1989-01-18 | 1990-06-12 | Merck & Co., Inc. | Coenzyme Q10 with HMG-CoA reductase inhibitors |
| US4922007A (en) | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5316765A (en) | 1989-09-07 | 1994-05-31 | Karl Folkers Foundation For Biomedical And Clinical Research | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies |
| CA2044162A1 (fr) | 1989-10-13 | 1991-04-14 | Jacques Borg | Derives des alcools gras a longue chaine, leurs applications, notamment en tant que molecules cytotrophes et cytoprotectrices, et compositions pharmaceutiques les contenant |
| US5101068A (en) | 1990-02-16 | 1992-03-31 | Prototek Inc. | Magnesium fluoromalonates |
| US5210272A (en) | 1990-02-16 | 1993-05-11 | Prototek, Inc. | Process for forming a fluoromethyl ketone |
| CA2036962C (en) | 1990-02-26 | 1998-09-15 | Ann E. Decamp | Process for the desilylation of a 4-silyloxy-tetrahydro-pyran-2-one |
| US5019651A (en) | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
| US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
| US5157025A (en) | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
| EP0519748B1 (en) | 1991-06-21 | 1998-09-02 | Merck & Co. Inc. | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme |
| EP0522576A3 (en) | 1991-07-12 | 1993-07-14 | Hoechst Aktiengesellschaft | Aminoethane-1,1-bisphosphonic acids and aminoethane-1,1-alkylphospinic/phosphonic acids, process of their preparation and their use |
| US5128328A (en) | 1991-10-25 | 1992-07-07 | American Home Products Corporation | Heterocyclic bisphosphonic acid derivatives |
| DE69320176T2 (de) | 1992-02-21 | 1999-04-08 | Merck & Co., Inc., Rahway, N.J. | Peptidylderivate und inhibitoren des interleukin-1-g(b)-konvertierenden enzyms |
| US5712396A (en) | 1992-10-28 | 1998-01-27 | Magnin; David R. | α-phosphonosulfonate squalene synthetase inhibitors |
| US5985838A (en) | 1993-04-29 | 1999-11-16 | Vertex Pharmaceuticals, Inc. | Peptide analogs as irreversible interleukin-1β protease inhibitors |
| US5639653A (en) | 1993-07-19 | 1997-06-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy | Method for proliferating Vγ2Vδ2 T cells |
| US5510517A (en) | 1993-08-25 | 1996-04-23 | Merck & Co., Inc. | Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids |
| TW257765B (enExample) | 1993-08-25 | 1995-09-21 | Merck & Co Inc | |
| US5712261A (en) * | 1993-10-04 | 1998-01-27 | Magnin; David R. | Method for preventing or treating hypertriglyceridemia |
| JP3674956B2 (ja) * | 1994-01-28 | 2005-07-27 | エーザイ株式会社 | 抗骨粗鬆症剤 |
| US5447922A (en) | 1994-08-24 | 1995-09-05 | Bristol-Myers Squibb Company | α-phosphonosulfinic squalene synthetase inhibitors |
| US5574025A (en) | 1994-10-26 | 1996-11-12 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferases |
| IL113246A (en) | 1995-04-04 | 2004-08-31 | Yissum Res Dev Co | Bisphosphonates and pharmaceutical compositions containing them |
| US5798442A (en) | 1995-04-21 | 1998-08-25 | Merck Frosst Canada, Inc. | Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases |
| US5618964A (en) | 1995-06-07 | 1997-04-08 | Bristol-Myers Squibb Company | Prodrug esters of phosphonosulfonate squalene synthetase inhibitors and method |
| JPH0930977A (ja) * | 1995-07-20 | 1997-02-04 | Tsuneo Nanba | 升麻抽出物を含有する骨疾患治療剤 |
| US6613544B1 (en) | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
| US5817816A (en) * | 1996-06-20 | 1998-10-06 | Meiji Seika Kaisha, Ltd. | Sesquiterpene derivatives having progesterone receptor binding inhibitory activity |
| US6083979A (en) | 1996-10-09 | 2000-07-04 | University Of Pittsburgh | Geranylgeraniol/lovastatin: a novel approach to blocking cancer transformation without cytotoxicity |
| US5777326A (en) * | 1996-11-15 | 1998-07-07 | Sensor Corporation | Multi-anode time to digital converter |
| US5763646A (en) | 1997-03-13 | 1998-06-09 | Ranbaxy Laboratories, Ltd. | Process for manufacturing simvastatin from lovastatin or mevinolinic acid |
| JPH11130670A (ja) | 1997-10-27 | 1999-05-18 | Oyo Seikagaku Kenkyusho | 骨粗鬆症治療剤 |
-
1999
- 1999-06-21 WO PCT/US1999/013967 patent/WO1999067809A1/en not_active Ceased
- 1999-06-21 EP EP99930492A patent/EP1088333A4/en not_active Withdrawn
- 1999-06-21 AU AU47025/99A patent/AU757104B2/en not_active Ceased
- 1999-06-21 US US09/336,950 patent/US6432931B1/en not_active Expired - Fee Related
- 1999-06-21 JP JP2000556389A patent/JP2002519305A/ja not_active Withdrawn
- 1999-06-21 CA CA002336201A patent/CA2336201A1/en not_active Abandoned
-
2001
- 2001-12-21 US US10/029,678 patent/US6699850B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002519305A5 (enExample) | ||
| RU2238736C2 (ru) | Фармацевтическая парентеральная композиция, содержащая бифосфонат | |
| AU761157B2 (en) | Method for inhibiting dental resorptive lesions | |
| AU2003229770B2 (en) | Bisphosphonic acid for the treatment and prevention of osteoporosis | |
| RU2002121643A (ru) | Фармацевтическая парентеральная композиция, содержащая бифосфонат | |
| EP1284754B1 (en) | Gel-like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts | |
| JP3479780B2 (ja) | 骨吸収を抑制する方法 | |
| JPH08505142A (ja) | 骨損失を治療及び予防するためのビスホスホネート／エストロゲン療法 | |
| NZ530113A (en) | Method for inhibiting bone resorption in a unit dosage form | |
| EP1781258A1 (en) | Formulations of bisphosphonates | |
| US6794371B1 (en) | Aminoalkylenephosphonates for treatment of bone disorders | |
| US20060233724A1 (en) | Medicinal composition for peridontal pocket administration containing bisphosphonic acid derivative or its salt as the active ingredient | |
| AU2012202489B2 (en) | Bisphosphonic acid for the treatment and prevention of osteoporosis | |
| WO2001028567A2 (en) | Aminoalkylenephosphonates for treatment of bone disorders | |
| IL153109A (en) | An effective pharmaceutical composition for inhibiting bone resorption in humans containing alendronic acid or its acceptable pharmaceutical salt or mixture |